Clinical trials: Liver Biomarkers
Beta Thalassemia Major
Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C
Thalassemics can develop liver fibrosis because of iron overload and hepatitis C infection. The latter is the main risk factor for liver fibrosis in transfusion dependent thalassemics.
- Trial name
- NCT02744547
- Testing
- Spirulina
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Tanta University
Obesity, NASH - Nonalcoholic Steatohepatitis
Diagnostic Accuracy of the "LLIFT", a Novel Non-invasive Biomarker for the Diagnosis of Non Alcoholic Fatty Liver (NAFL) and SteatoHepatitis (NASH) in a Population With High Risk of Metabolic Syndrome"
The NAFLD is the first cause of liver disease worldwide. The severe form of NAFLD, the NASH progresses to cirrhosis and is responsible of liver mortality.
- Trial name
- LLIFT (NCT04616664)
- Where
- 7 sites in France
- Volunteers
- 158 people
- Sponsor
- University Hospital, Lille
Cancer, Hepatocellular, Radiotherapy Side Effect
A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer
The purpose of this study is to evaluate the role of quantitative MR imaging and blood-based biomarkers to measure liver function in patients receiving radiation therapy for liver cancer or cancer that has spread to the liver.
- Trial name
- HepQuant (NCT06144827)
- Testing
- Multiparametric MRI scans, Multiparametric MRI scans + HepQuantShunt Test
- Sponsor
- Montefiore Medical Center
Polycystic Ovary Syndrome (PCOS), Metabolic Dysfunction-Associated Steatotic Liver Disease
Biomarker Panel for PCOS-Associated Liver Steatosis in Adolescent Girls (COMPASS-pedPCOS)
This single-center, prospective, observational, cross-sectional mechanistic pilot study will evaluate whether polycystic ovary syndrome (PCOS) contributes to hepatic steatosis in adolescent girls independently of adiposity.
- Conditions
- Polycystic Ovary Syndrome (PCOS), Metabolic Dysfunction-Associated Steatotic Liver Disease, Pediatric Obesity, Hyperandrogenism
- Trial name
- COMPASSpedPCOS (NCT07731373)
- Testing
- Extended Serum Biomarker and Hormonal Panel, Liver Elastography with Controlled Attenuation Parameter, Targeted Genotyping of PNPLA3 rs738409 and HSD17B13 rs72613567
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Kayseri City Hospital
Metabolic Dysfunction-associated Liver Disease
Effect of Plant-based Diets on Liver Biomarkers, Cardiometabolic Health, and Exposure to Environmental Contaminants and Endocrine Disruptors in Patients With Metabolic Liver Disease.
Plant-based diets have gained increasing recognition for their sustainability and their benefits on cardiometabolic and liver health.
- Trial name
- ESTEATOVEG (NCT07503431)
- Testing
- Traditional Mediterranean diet, Vegan Mediterranean diet
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Miguel López Moreno
Liver Cancer
Displacement Distance and Stabilization Time for Liver Fiducial Marker
Liver malignant tumor, including liver cancer and liver metastasis, is common in China [1]. Previous studies have shown that cyber-knife stereotactic radiotherapy is effective and safe for locally advanced liver malignancies with…
- Trial name
- NCT05816837
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Peking University Third Hospital
Liver Fibrosis
A Potential Novel Marker for Liver Fibrosis in NASH: the Soluble Secreted Form of the Human Asialoglycoprotein Receptor
Soluble secreted proteins that are expressed uniquely in specific organs and whose formation of secretion is regulated by disease states are excellent markers for the disease.
- Trial name
- NCT00941902
- Where
- Israel
- Volunteers
- 148 people
- Sponsor
- Ziv Hospital
Liver Cirrhosis
Predictive Utility of DASIMAR as a Prognostic Biomarker in Acute-on-chronic Liver Failure (ACLF)
Patients with acute on chronic liver failure have a risk of developing multiorgan failure and a high mortality. The current scoring systems defining the outcome of patients with acute decompensation of cirrhosis fail to identify…
- Trial name
- DASIMAR (NCT01071746)
- Where
- United Kingdom
- Volunteers
- 700 people
- Sponsor
- University College London Hospitals
Hepatocellular Carcinoma (HCC)
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
This is a prospective, observational, single-center study. The purpose of this study is to evaluate the efficacy of circulating tumor mitochondrial DNA (ct-mtDNA) in plasma as a biomarker for minimal residual disease (MRD)…
- Trial name
- CCGLC-015 (NCT06653062)
- Testing
- Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tongji Hospital
NAFLD, NASH
LITMUS Imaging Study
The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD).
- Conditions
- NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver
- Trial name
- NCT05479721
- Where
- 18 sites in United States, Finland and 8 more
- Volunteers
- 450 people
- Sponsor
- University of Oxford
Colorectal Liver Metastases (CRCLM), Unresectable Colorectal Liver Metastases
Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable Patients With Colorectal Liver Metastases
This is a observational, prospective, single arm, proof of concept study to assess safety, feasibility, and potential efficacy of combining Yttrium-90 transarterial radioembolization(TARE) with standard systemic therapy in…
- Trial name
- YRENE (NCT07406126)
- Testing
- Yttrium-90 Radioembolization with standard systemic therapy
- Where
- 5 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fernando Gómez Muñoz
Fatty Liver
Alpha-Glutathione-S-Transferase (AlphaGST) and MARINA Index in Metabolic-Dysfunction-Associated-Steatotic-Liver-Disease (MASLD)
AlphaGST represents a liver enzyme whose serologic levels progressively increase in alcoholic and viral chronic hepatitis according to the worsening of liver fibrosis.
- Trial name
- NCT05804955
- Where
- Italy
- Volunteers
- 260 people
- Sponsor
- University of Campania Luigi Vanvitelli
Cancer, Solid Tumor
Exploring Cancer-Associated Thromboembolism Prognosis Biomarkers and Polymorphisms
This study aims to assess biomarkers and their related polymorphisms in the context of cancer-associated thromboembolism, with a particular focus on their interaction with the immune system.
- Conditions
- Cancer, Solid Tumor, Thromboembolism, Cardiovascular Diseases
- Trial name
- CAT_PB (NCT06065592)
- Testing
- Palbociclib, Rivaroxaban, SNP
- Where
- 2 sites in Lebanon
- Volunteers
- 500 people
- Sponsor
- Lebanese University
Obesity, Colon Cancer
Proteomic Analysis of Patients Undergoing Bariatric Surgery
The expression of proteins in the blood of obese individuals is different from the expression of proteins in healthy individuals, and is also different in individuals after bariatric surgery.
- Conditions
- Obesity, Colon Cancer, Thyroid Cancer, Esophageal Cancer
- Trial name
- NCT06787807
- Testing
- bariatric surgery
- Where
- Brazil
- Volunteers
- 103 people, healthy volunteers welcome
- Sponsor
- Universidade Federal de Pernambuco
Non-alcoholic Fatty Liver Disease
Validity of Laboratory Biomarkers in Diagnosis of Nonalcoholic Fatty Liver Disease (NAFLD) and It's Consequences
The validity of laboratory biomarkers in the diagnosis of NAFLD is still not established, and adherence to a healthy dietary lifestyle for those patients in our community is not well studied.
- Trial name
- NCT06908122
- Testing
- laboratory biomarkers in the diagnosis of NAFLD disease
- Volunteers
- 100 people
- Sponsor
- Assiut University
Hepatocellular Carcinoma
Evaluation of AKR1B10 as a New Marker for Interventional Therapy of Hepatocellular Carcinoma
Primary liver cancer is currently the fourth most common malignant tumor and the second leading cause of tumor mortality in China, posing a serious threat to the lives and health of the Chinese people .
- Trial name
- NCT06272656
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Hebei Medical University Third Hospital
Liver Transplant Rejection
TRU-IMMUNO: Optimizing Liver Immunosuppression
This is a prospective, multi-center, randomized study. The primary objective is to evaluate the feasibility and utility of TruGraf/TRAC Liver testing used in addition to standard of care measures of liver dysfunction to guide…
- Trial name
- NCT05335551
- Testing
- Patients monitored with TruGraf and TRAC Liver testing
- Volunteers
- 130 people
- Sponsor
- Transplant Genomics, Inc.
Obesity, Morbid, Bariatric Surgery Candidate
Investigation of Microbiome-based Prognostical Biomarkers in Patients With Morbid Obesity and Bariatric Surgery
Morbid obesity leads to non-alcoholic fatty liver disease (NAFLD), and not all NAFLD cases benefit from weight loss e.g. after bariatric surgery.
- Conditions
- Obesity, Morbid, Bariatric Surgery Candidate, NAFLD, Microbiome
- Trial name
- NCT03391401
- Testing
- Bariatric surgery
- Where
- 2 sites in Germany
- Volunteers
- 204 people
- Sponsor
- St. Franziskus Hospital
Hepatocellular Carcinoma, Liver Disease
An Analysis of Urinary Proteases as Biomarkers for Hepatocellular Carcinoma-101423
Specific urine proteases or groups of these enzymes can be reliable biomarkers and an effective gauge of response to therapy in patients with hepatocellular carcinoma.
- Trial name
- NCT01316679
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Liver Dysfunction
Assessing Changes in Gadoxetate Metabolism by the Liver Using MRI
Identifying drugs at risk of interacting with other drugs, called drug-drug interaction (DDI), early in their development is crucial in avoiding late-stage drug development failures.
- Trial name
- NCT07541807
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust